GBABA

合作夥伴

Menu

HKG Epitherapeutics CEO Delivered a Keynote Presentation at BIOHK2023

View Original Content: HKG Epitherapeutics CEO Delivered a Keynote Presentation at BIOHK2023 (prnewswire.com)

Presentation Highlights the Implications of DNA Methylation for Early Disease Prediction, Prevention and Intervention

HONG KONG, Sept. 18, 2023 /PRNewswire/ — HKG Epitherapeutics (“HKG” or the “Company”), a commercial-stage biotech company developing novel tools for the early detection of cancer and promoting healthy aging, announced that its CEO, Prof. Moshe Szyf, delivered a keynote presentation at BIOHK2023 titled, “DNA methylation in health and disease; implications for early prediction, prevention and intervention.” The event took place in Hong Kong, China on September 13-16, 2023.

“The advancements HKG has made in DNA methylation research have been pivotal in advancing a holistic approach to healthcare. Testing has always lagged treatment options, and by improving testing, we are improving outcomes for patients and increasing their life and healthspans,” said Prof. Szyf. “HKG’s early cancer detection tests for liver, cervical and pancreas cancer are revolutionizing how we diagnose cancer by utilizing distinct methylation profiles that categorically differentiate cancerous tissues from healthy ones. Early detection can lead to earlier treatments and better outcomes. Plainly said, better testing saves lives.”

Epigenetics is the study of how development, behaviors and environment can impact the way a person’s genes work. DNA methylation is an epigenetic mechanism that cells use to control gene expression. During embryonic development, normal DNA profiles are laid down, which are crucial for maintaining healthy mental and physical functioning. Disruption to the normal DNA methylation profile has been shown to trigger cancer.

Additionally, in recent years, emerging data from both HKG’s laboratory and others has shed light on “epigenetic programming,” and how DNA reflects lifelong interactions between multiple environments, ultimately impacting a person’s overall physical and mental health. DNA methylation serves as a dynamic health barometer, offering a framework for disease detection, prevention and intervention.

Continued Prof. Szyf, “We have learned that our biological age does not always align with our chronological age. You may be older than you actually are! Why? Social and physical factors play a significant role in influencing DNA. The question is, how do we actually determine biological age and what do we do with this information? Products like epiAge are increasingly important in supporting the quest for healthy aging by equipping consumers with valuable epigenetic insights and the knowledge to take proactive measures to lead longer, healthier lives.”

About HKG Epitherapeutics
HKG Epitherapeutics is a commercial-stage biotech company developing novel tools for the early detection of cancer and promoting healthy aging. Through translating its pioneering epigenetic research into innovative medical and consumer-focused tests, HKG provides valuable genetic insights that empower healthcare professionals and individuals to adopt a more personalized, proactive approach to healthcare. For more information, visit https://hkgepitherapeutics.com/.

Media Contacts
Raquel Cona / Michaela Fawcett
KCSA Strategic Communications
rcona@kcsa.com / mfawcett@kcsa.com

SOURCE HKG Epitherapeutics

View Original Content: HKG Epitherapeutics CEO Delivered a Keynote Presentation at BIOHK2023 (prnewswire.com)

網絡擴展。商業開發。最新消息。生物科技洞見。

  • 粵港澳大灣區生物科技聯盟著眼於促進生物科技的發展，將眾多生物科技利益持份者聚集在大灣區。
  • 了解更多會員權益，或即刻點擊下方按鈕加入我們！
立即加入
  • @GBABA
  • @GBABA
  • @GBABA

地址一

香港新界沙田香港科學園科技大道西9號生物科技中心一座6樓601-605室

Hong Kong Science Park, Shatin, New Territories, Hong Kong

地址二

深圳市龍華區觀光路1301號銀星科技園智界二期1號B座3層

Longhua District, Shenzhen

電話

+852 2799 7688

傳真

+852 2111 9762

電郵

info@biogba.com

Close Menu
繁體中文
繁體中文 English 簡体中文